Showing 1921-1930 of 4166 results for "".
- Haag-Streit Launches the Eyestar 900 Anterior Chamber Suitehttps://modernod.com/news/haag-streit-launches-the-eyestar-900-anterior-chamber-suite/2480794/Haag-Streit has announced the launch of the Eyestar 900 Anterior Chamber Suite (AC-Suite) to compliment the Cataract Suite. The AC-Suite is designed to meet the growing demand for improved outcomes in cataract and refractive surgery. The Eyestar 900 is based on swep
- Myco Industries Debuts AB Max Advanced for Treatment of Anterior Blepharitishttps://modernod.com/news/myco-industries-debuts-ab-max-advanced-for-treatment-of-anterior-blepharitis/2476354/Myco Industries released AB MAX, a new treatment for anterior blepharitis. The AB MAX is an adapter that allows eye care professionals to increase the functionality of their Algerbrush by converting it into a multi-purpose device for treatment of the same conditions as a standard Algerbrush, as w
- Hilco Vision Acquires Simovision BVhttps://modernod.com/news/hilco-vision-acquires-belgium-and-netherlands-based-simovision-bv/2480473/Hilco Vision has acquired Simovision BV, effective November 17, 2021.
- Arctic Vision Announces Exclusive Licensing Agreement With ActualEyeshttps://modernod.com/news/arctic-vision-announces-exclusive-licensing-agreement-with-actualeyes/2479210/Arctic Vision and ActualEyes, a clinical stage Japanese biotech company committed to the research and development of cell therapy for corneal endothelial diseases, jointly announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product cand
- Samsara Vision and Medevise Consulting Announce European Partnershiphttps://modernod.com/news/samsara-vision-and-medevise-consulting-announce-european-partnership/2478956/Samsara Vision announced it will partner with Medevise Consulting to build a dedicated commercial organization to support Samsara Vision’s Tsert SI Implantable Miniature Telescope (IMT) (by Isaac Lipshitz). The two companies will collaborate to advance clinical research, coordinate reimbursement,
- SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conferencehttps://modernod.com/news/sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference/2481654/With a goal to improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference taking place from June 9-11 in Manchester, England. Three-Year Myopia Control Eff
- KYS Vision Reports Clinical Trial Results of Its Remote Physiologic Monitoring System for Patients With Chronic Retinal Conditionshttps://modernod.com/news/kys-vision-reports-clinical-trial-results-of-its-remote-physiologic-monitoring-system-for-patients-with-chronic-retinal-conditions/2481207/KYS Vision announced clinical trial results of its Macustat macular function scan for the remote monitoring of central retinal function. The study was published in the peer-reviewed journal Digital Health1 in October 2022. The study is one
- Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announces-positive-post-hoc-analysis-from-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2481147/Kubota Vision announced positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease. The primary objective of this study was to determine if emixustat re
- Kubota Vision Announces End-of-Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announced-end-of-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2480932/Kubota Vision announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (emixustat) in patients with macular atrophy secondary to Stargardt disease. The study was a multicenter, randomized, double-masked, and placebo-controlled phase 3 clini
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro